Autonomix Meeting Shows What an FDA Pre-Submission Can and Cannot Settle

Autonomix Medical said on Sept. 30 that it had completed a pre-submission meeting with the Food and Drug Administration about a standalone transvascular sensing platform, and that based on the feedback it believes it has identified a Class II regulatory pathway, according to the company's press release, distributed by GlobeNewswire and republished by Finviz. The Woodlands, Texas, company said the route "would use an already-cleared reference device to support a substantial-equivalence strategy," and that it is targeting potential US clearance in about 15 months, subject to development, validation and FDA review.

The release is the company's own account of the meeting and of how it reads FDA's feedback. What a pre-submission is, and what it is not, is set out in FDA's guidance on the program.

What a Pre-Submission is

Pre-Submissions, or Pre-Subs, are the best-known part of FDA's Q-Submission Program, named for the "Q" numbers the agency uses to track them. FDA's final guidance on the program, issued in May 2025, describes the ways a company can ask for written feedback or a meeting before or during a range of submissions, including 510(k)s, De Novo requests, premarket approval applications, Humanitarian Device Exemptions and investigational device exemptions.

According to the guidance document, a Pre-Sub is a formal written request for FDA feedback, answered in a formal written response or, if the company chooses, written feedback followed by a meeting held in person or by video or teleconference. The request should pose specific questions on review topics, such as biocompatibility, bench testing or cybersecurity. If there is a meeting, the company drafts the minutes and submits them to FDA for review, within 15 days under the guidance.

The program is voluntary. FDA says in the guidance that early interaction on planned studies may improve the quality of later submissions and shorten total review times, and that feedback is most effective when requested before testing is carried out.

How long it takes

The timelines grew out of user-fee agreements. The guidance says FDA and industry refined the program's meeting scheduling and set a performance goal for the timing of Pre-Sub feedback under the Medical Device User Fee Amendments of 2017, and refined those goals again in the 2022 agreement.

Under the table in the guidance, FDA sends written feedback within 70 days of receiving a Pre-Sub, or five days before a scheduled meeting if that is sooner, and meetings are typically set around day 70 to 75 by mutual agreement. The guidance notes that meeting minutes and materials, like other agency records, may be subject to Freedom of Information Act requests.

What it does not settle

The guidance draws clear limits. A Pre-Sub is meant to help guide product development or submission preparation, but it is not intended to be a pre-review of a planned submission or of the data in it. Reviewing information in a Pre-Sub does not guarantee a favorable decision on a future submission, FDA says, and reviewers may raise new questions once the full application is in hand or if new information emerges.

The obligations run both ways but loosely. Issues FDA raises in a Pre-Sub do not bind the company to resolve them, according to the guidance, though a later submission should explain why it took a different approach or left an issue unresolved. Like other FDA guidance documents, the Q-Sub guidance itself carries the label that it contains nonbinding recommendations.

Autonomix's release makes the same distinction in its own terms. It says the company's technology "is investigational and has not yet been cleared for marketing in the United States," and that clearance of the sensing platform could, in the company's view, establish a predicate for later versions of its system.